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Alan is a frequent guest speaker in different parts of 
the world. However his hosts, be they policy makers, 
clinicians or health service managers, are seldom soothed by 
congratulations on their latest reform attempts or offered the 
latest panacea from the National Health Service in England. 
Rather, they are challenged to specify their objectives and 
to support their strategies with data and evidence. Alan was 
always particularly annoyed at reorganisation that passed 
as reform – successive “re-disorganisation” as he termed it 
– which consumed scarce resources in terms of funds and 
labour.
A systematic approach to international comparative health 
policy became possible with the advent of national health 
accounts. The collection, classification and publication of 
health care expenditure data was not implemented until the 
1970s. Once introduced, this allowed for valid comparisons 
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of healthcare costs weighed against what was achieved in 
terms of life expectancy. It was soon demonstrated that higher 
health spending was not an assured path to improving health 
outcomes, at least as reflected by longevity. Developments in 
the range of data collected, the number of countries using the 
same systems of classification, and econometric techniques 
for analysis have led to increasingly sophisticated forms of 
international comparison, but also more opportunities for 
drawing misleading conclusions. A great deal of effort has 
been directed towards determining the ranking of nations’ 
performance. And a common international belief has 
been that increasing funding and reorganising governance 
and delivery systems will solve the problems. But one of 
Alan’s insights in the international policy arena was that the 
performance of health systems across the world is actually 
very similar, despite great differences in history, culture and 
the public-private mix of funding and provision.
All countries are facing challenges with increasing cost 
pressures, reducing unwarranted variations in practice, 
improving the provision of effective treatment, generally 
increasing technical efficiency, and above all, ensuring 
value for money. This has given a focus to international 
comparisons based on reform within the system, or within 
particular parts of it. The publication of Alan’s edited 
volume on the public-private mix for health is an eminent 
example of this endeavour, digging beneath and around 
the data to understand the context, but not replacing facts 
by anecdote or opinion.1 “Management by measurement” 
is the Maynard approach. Alan has always emphasised that 
the patient should be at the centre of why we are trying 
to manage healthcare better. For many years he has been a 
staunch advocate of patient relevant outcomes, seeing them 
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as the most important indicator of success of healthcare. 
Now PROMS – Patient Reported Outcome Measures – 
and PREMS – Patient Reported Experience Measures – 
are increasingly routinely collected, reported and used in 
healthcare systems worldwide.
A recurring theme in many of Alan’s writings over the 
years is the importance of getting the incentives right. 
For too long the debate addressed the contrast between 
fixed budget or capitation approaches versus payment 
for activity/fee for service approaches. The evidence that 
fixed budgets encourage risk selection and skimping on 
activity, while paying for the volume of services delivered 
leads to higher levels of activity, has been clear for decades. 
And neither approach provides positive incentives for 
quality improvement. Over recent years, more interesting 
experiments have emerged in many countries, using blended 
payments to ameliorate the perverse incentives of any single 
payment mechanism. Early attempts were often quite blunt 
and tended to have little effect as the incentives were poorly 
designed and the rewards too small; or they were extremely 
costly and often over-rewarded existing practice. Careful 
attention to the design of payment schemes with clear 
identification of the objectives and rigorous evaluation with 
an eye open to unintended effects, remain as important as 
ever. Alan has set the precedent for health economists in this 
regard.
Health reform is often beset by ideology passing as reform 
and self-interest passing as principles. Alan and I published 
a piece in 2005, analysing the Australian conservative 
government reforms that expanded the reach of the private 
insurance sector, with significant public subsidies, in the face 
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of an electorally popular, publicly funded comprehensive 
set of entitlements under Medicare.2 The proposed benefits 
of relieving pressure on public hospitals, providing the 
public with more choice of provider, and reducing private 
insurance premiums remained illusory; yet the politics were 
successful. This represents another of Alan’s contributions 
to international health policy and reform – the recognition 
of the power of ideology in shaping how problems are 
conceptualised and solutions are developed. Different 
ideologies are more or less prevalent in different countries, 
but in all there is a rivalry at the heart of the system as private 
providers seek to protect and advance their interests.
In his book, The Public-Private Mix for Health, published in 
2005, Alan could conclude that the challenges of health 
care reform, although better articulated over the previous 
twenty years, remained largely unmet. “The characteristic 
of health care”, he wrote, “is its resistance to change.” A 
few years later writing in the Oxford Handbook, he noted 
various successes of health economics in making inroads 
to system reform.3 First, health technology assessment has 
become commonplace through the role of the National 
Institute for Health and Care Excellence (NICE) in the 
UK, the Pharmaceutical Benefits Advisory and the Medical 
Services Advisory Committees in Australia and in a number 
of other countries. Second, the development of routine 
patient reported measures, PROMS and PREMs, as noted 
already, has become common in many countries. Third, 
there is wider adoption of incentive compatible payment 
systems, whether it is activity based funding for hospitals, or 
blended payment methods for providers. A further addition 
I will make is the end of the widespread belief that the 
problems of health care worldwide can only be solved by 
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increased funding. However, that seems to be due more 
to the exigencies imposed by the Global Financial Crisis of 
2007 – 08, than the proselytizing of health economists.
Now, more than ever, we must have clarity around the goals 
of efficiency, equity and expenditure control. Reform should 
be evidence based, cautious in implementation and subject 
to rigorous evaluation. These are challenges that Alan has 
always posed to the politicians involved in successive “re-
disorganisations” of healthcare systems; but they also set the 
agenda for us as health economists wishing to make the same 
contribution to the international policy debate as Alan has 
done for many years.
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